We are live on
!
Find out more
PBM
Propel Bio Management Portfolio holdings
AUM
$159M
1-Year Est. Return
60.94%
This Fund
S&P 500
This Quarter
Est. Return
+17.45%
1 Year Est. Return
+60.94%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$99.9M
AUM Growth
+$17.5M
(+21%)
Cap. Flow
+$8.31M
Cap. Flow
% of AUM
8.32%
Top 10 Holdings %
Top 10 Hldgs %
87.06%
Holding
21
New
5
Increased
2
Reduced
3
Closed
5
Top Buys
| 1 |
Milestone Pharmaceuticals
MIST
|
+$5.86M |
| 2 |
Celldex Therapeutics
CLDX
|
+$3.59M |
| 3 |
Jasper Therapeutics
JSPR
|
+$3.12M |
| 4 |
Delcath Systems
DCTH
|
+$2.37M |
| 5 |
CMPS
Compass Pathways
CMPS
|
+$2.29M |
Top Sells
| 1 |
Achieve Life Sciences
ACHV
|
+$6.5M |
| 2 |
Phathom Pharmaceuticals
PHAT
|
+$3.82M |
| 3 |
Capricor Therapeutics
CAPR
|
+$695K |
| 4 |
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
|
+$423K |
| 5 |
TScan Therapeutics
TCRX
|
+$274K |
Sector Composition
| 1 | Healthcare | 76.77% |
| 2 | Energy | 23.23% |
Similar funds
OS
OC
JF
1L
USWIA
AWP
RWM
EWA